Nearly 100 million Americans will experience a psychiatric or neurological disorder at some point in their lives. These are friends, family and neighbors wrestling with the debilitating symptoms of depression; vibrant young people dealing with lives torn at the seams by schizophrenia; and parents and grandparents struggling to preserve their sense of self against neurodegenerative disorders like Parkinson’s disease and Alzheimer’s disease.
At Lundbeck, we believe life is too precious to be interrupted by brain diseases. Combining the logic of science with our passion for making a difference to patients, we strive to advance understanding of the complex workings of the brain.
While brain research is riskier and more expensive than other therapeutic areas because it takes longer to develop treatments for brain diseases than other pharmaceutical products, Lundbeck is uncompromisingly committed to the research and development of therapies for people living with significant psychiatric and neurological disorders.
For more than 70 years, we have been at the forefront of neuroscience research. We have a deep heritage of discovery and have brought breakthrough therapies to millions of people. And we're just getting started.
In the Newsroom
Dr. Doug Williamson, Lundbeck's chief medical officer and VP of US Medical, answers questions about progress and bright spots in Parkinson’s research.
In the Newsroom
Lundbeck's Dr. Bruce Kinon on the challenges related to treating negative symptoms of schizophrenia and new directions in negative-symptom research.